News

Biogen (NASDAQ: BIIB) and Eli Lilly (NYSE: LLY) both have Alzheimer's drugs that are in development and could obtain approval from the Food and Drug Administration (FDA) within the next 12 months

Biogen (NASDAQ: BIIB) and Eli Lilly (NYSE: LLY) both have Alzheimer's drugs that are in development and could obtain approval from the Food and Drug Administration (FDA) within the next 12 months

Biogen (NASDAQ: BIIB) and Eli Lilly (NYSE: LLY) both have Alzheimer's drugs that are in development and could obtain approval from the Food and Drug Administration (FDA) within the next 12 months

Inflation rates may finally be cooling down from last year's unnerving levels. However, prices are still rising at a pace above long-term averages, so consumers can't breathe easy just yet -- and

Inflation rates may finally be cooling down from last year's unnerving levels. However, prices are still rising at a pace above long-term averages, so consumers can't breathe easy just yet -- and

Inflation rates may finally be cooling down from last year's unnerving levels. However, prices are still rising at a pace above long-term averages, so consumers can't breathe easy just yet -- and

Shares of the clinical-stage metabolic disorder specialist Viking Therapeutics (NASDAQ: VKTX) were down by 6.45% on moderate volume as of 1:42 p.m. ET Thursday afternoon. The drugmaker's shares are

There's been lots of excitement surrounding Novavax (NASDAQ: NVAX). The company beat earnings expectations for the first quarter as it has been slashing expenses, and recent clinical trials --

Companies that produce generic drugs aren't known for being exciting investments, and there's little chance they'll ever expand as fast as your average tech stock or most other growth stocks. If

Companies that produce generic drugs aren't known for being exciting investments, and there's little chance they'll ever expand as fast as your average tech stock or most other growth stocks. If

Axsome Therapeutics (NASDAQ: AXSM) wowed investors late last year with strong data from a phase 3 study of AXS-05, its candidate treatment for Alzheimer's disease agitation. AXS-05 met its primary

Deal or no deal? That's now the big question for investors concerning Amgen's (NASDAQ: AMGN) pending $28 billion acquisition of Horizon Therapeutics (NASDAQ: HZNP).

The Federal Trade Commission

Deal or no deal? That's now the big question for investors concerning Amgen's (NASDAQ: AMGN) pending $28 billion acquisition of Horizon Therapeutics (NASDAQ: HZNP).

The Federal Trade Commission

Deal or no deal? That's now the big question for investors concerning Amgen's (NASDAQ: AMGN) pending $28 billion acquisition of Horizon Therapeutics (NASDAQ: HZNP).

The Federal Trade Commission

Income investing is a tried-and-true investing strategy. This is because businesses that pay consistent and growing dividends to shareholders are often mature businesses that can't possibly reinvest

Income investing is a tried-and-true investing strategy. This is because businesses that pay consistent and growing dividends to shareholders are often mature businesses that can't possibly reinvest

Income investing is a tried-and-true investing strategy. This is because businesses that pay consistent and growing dividends to shareholders are often mature businesses that can't possibly reinvest

For more crisp and insightful business and economic news, subscribe to The Daily Upside newsletter It's completely free and we guarantee you'll learn something new every day.

Big Pharma needs

For more crisp and insightful business and economic news, subscribe to The Daily Upside newsletter It's completely free and we guarantee you'll learn something new every day.

Big Pharma needs

For more crisp and insightful business and economic news, subscribe to The Daily Upside newsletter It's completely free and we guarantee you'll learn something new every day.

Big Pharma needs